Bristol-Myers Squibb (NY:BMY)

Topics Economy

Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes

November 05, 2025

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

November 03, 2025

Via Benzinga

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership ↗

November 03, 2025

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.

Via Benzinga

Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades' ↗

November 03, 2025

Cleveland-Cliffs shares gained 1.4% to close at $12.43 on Friday while Bristol-Myers Squibb shares gained 1% to close at $46.07.

Via Benzinga

Bristol Myers Squibb Co (NYSE:BMY) Presents a Compelling Value Investment Case ↗

November 03, 2025

Bristol Myers Squibb (BMY) offers strong value with a low P/E ratio, high profitability, and a robust 5.38% dividend yield, despite patent challenges.

Via Chartmill

Topics Intellectual Property

BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025 ↗

October 30, 2025

Via Stocktwits

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025

November 03, 2025

Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes

November 03, 2025

Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant...

Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout

October 31, 2025

Bristol-Myers Squibb Co (NYSE:BMY) Offers a Compelling Mix of High Yield and Dividend Growth ↗

Topics Intellectual Property

October 31, 2025

Discover Bristol-Myers Squibb (BMY), a top dividend stock with a strong 5.82% yield, consistent growth, and solid profitability for reliable income.

Via Chartmill

Discover which S&P500 stocks are making waves on Thursday. ↗

October 30, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why

October 30, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its...

Via StockStory

Topics Artificial Intelligence Earnings

Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook ↗

October 30, 2025

Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblozyl, Camzyos, and Breyanzi.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 30, 2025

Via Benzinga

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3

October 30, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year...

Via StockStory

Bristol Myers Squibb Co (NYSE:BMY) Q3 2025 Earnings Beat Estimates ↗

October 30, 2025

Bristol Myers Squibb Q3 2025 earnings beat estimates with $1.63 EPS and $12.22B revenue, driven by strong new product sales.

Via Chartmill

Topics Earnings

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...

Via Benzinga

Topics Economy

Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

October 30, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.

What to Expect from Bristol-Myers Squibb's Earnings ↗

October 29, 2025

Via Benzinga

Bristol-Myers Squibb (BMY) To Report Earnings Tomorrow: Here Is What To Expect

October 28, 2025

Via StockStory

Topics Artificial Intelligence

3 Dividend-Paying Drug Stocks to Buy at a Discount ↗

October 27, 2025

Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

October 27, 2025

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal ↗

October 27, 2025

Via Benzinga

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025

October 25, 2025

Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment

October 24, 2025

San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly...

Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through.

Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks ↗

October 22, 2025

Via The Motley Fool

Topics Workforce

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...